Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.

被引：0

作者：

Rahbar, Kambiz

Essler, Markus

Eiber, Matthias

La Fougere, Christian

Prasad, Vikas

Fendler, Wolfgang P.

Rassek, Philipp

Hasa, Ergela

Dittmann, Helmut

Bundschuh, Ralph A.

Pabst, Kim M.

Kurtinecz, Milena

Sandstrom, Per

Verholen, Frank

Sartor, A. Oliver

机构：

[1] Univ Hosp Munster, Dept Nucl Med, Munster, Germany

[2] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany

[3] Tech Univ Munich, Dept Nucl Med, Munich, Germany

[4] Univ Hosp Tubingen, Dept Nucl Med & Clin Mol Imaging, Tubingen, Germany

[5] Univ Ulm, Dept Nucl Med, Ulm, Germany

[6] Univ Hosp Essen, Dept Nucl Med, German Canc Consortium DKTK, Essen, Germany

[7] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[8] Bayer Consumer Care, Basel, Switzerland

[9] Tulane Med Sch, Tulane Canc Ctr, New Orleans, LA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5040

引用

页数：1

共 50 条

[1] Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra): The RALU Study
Rahbar, K.
Essler, M.
Eiber, M.
La Fougere, C.
Prasad, V.
Fendler, W. P.
Rassek, P.
Hasa, E.
Dittmann, H.
Bundschuh, R. A.
Pabst, K. M.
Kurtinecz, M.
Schmall, A.
Verholen, F.
Sartor, O.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S54 - S55
[2] Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes
Rahbar, K.
Essler, M.
Eiber, M.
la Fougere, C.
Prasad, V.
Fendler, W. P.
Rassek, P.
Hasa, E.
Dittmann, H.
Bundschuh, R. A.
Pabst, K. M.
Kurtinecz, M.
Schmall, A.
Verholen, F.
Sartor, O.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1180 - S1180
[3] Time interval between radium-223 (223Ra) therapy and Lutetium-177-prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study.
Rahbar, Kambiz
Essler, Markus
Eiber, Matthias
la Fougere, Christian
Prasad, Vikas
Pabst, Kim M.
Fendler, Wolfgang Peter
Rassek, Philipp
Hasa, Ergela
Dittmann, Helmut
Bundschuh, Ralph A.
Kurtinecz, Milena
Schmall, Anja
Verholen, Frank
Sartor, A. Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[4] Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
Rahbar, Kambiz
Essler, Markus
Pabst, Kim M.
Eiber, Matthias
la Fouge, Christian
Prasad, Vikas
Rassek, Philipp
Hasa, Ergela
Dittmann, Helmut
Bundschuh, Ralph A.
Fendler, Wolfgang P.
Kurtinecz, Milena
Schmall, Anja
Verholen, Frank
Sartor, Oliver
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 574 - 578
[5] Safety and effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen in patients with metastatic castration-resistant prostate cancer with and without visceral metastases who had received prior radium-223: a post hoc analysis of the RALU study
Rahbar, Kambiz
Essler, Markus
Eiber, Matthias
la Fougere, Christian
Prasad, Vikas
Pabst, Kim
Fendler, Wolfgang
Rassek, Philipp
Hasa, Ergela
Dittmann, Helmut
Bundschuh, Ralph
Kurtinecz, Milena
Schmall, Anja
Verholen, Frank
Sartor, Oliver
JOURNAL OF NUCLEAR MEDICINE, 2023, 64
[6] Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).
Sartor, A. Oliver
la Fougere, Christian
Essler, Markus
Ezziddin, Samer
Kramer, Gero
Ellinger, Joerg
Nordquist, Luke T.
Sylvester, John
Paganelli, Giovanni
Peer, Avivit
Boegemann, Martin
Meltzer, Jeffrey
Sandstrom, Per
Song, Danny
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study
Song, D.
Zimberg, S. H.
Conti, P.
la Fougere, C.
Essler, M.
Kramer, G.
Ellinger, J.
Sylvester, J. E.
Paganelli, G.
Peer, A.
Boegemann, M.
George, S.
Tomaszewski, J.
Meltzer, J.
Sandstrom, P.
Babajanyan, S.
Nordquist, L.
Sartor, O.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E854 - E855
[8] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Tombal, B.
Goebell, P. J.
Shore, N. D.
George, D. J.
Pinto, A.
Sartor, O.
Meltzer, J.
Verholen, F.
Schmall, A.
Saad, F.
ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
[9] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Hijab, A.
Tunariu, N.
Tovey, H.
Alonzi, R.
Tree, A.
Staffurth, J.
Blackledge, M.
Padhani, A. R.
Stidwill, H.
Finch, J.
Chatfield, P.
Perry, S.
Koh, D-M.
Hall, E.
Parker, C.
ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
[10] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Conti, Peter
George, Saby
Tomaszewski, Jeffrey
Song, Daniel
Harshman, Lauren
Nordquist, Luke
Sandstrom, Per
Bayh, Inga
Babajanyan, Svetlana
Sartor, Oliver
JOURNAL OF NUCLEAR MEDICINE, 2020, 61

← 1 2 3 4 5 →